ClinicalTrials.gg
CompletedNCT01192906Updated Nov 2, 2016

A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309)

A Phase 3 interventional study of Placebo and bitopertin [RO4917838] in Schizophrenia, sponsored by Hoffmann-La Roche. Completed at 113 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-02.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
624
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Schizophrenia by Hoffmann-La Roche — none open to participants now, none under way, none of them phase 3. Schizophrenia · Hoffmann-La Roche.

Enrollment
3rd of 16
624 · median 294
Started
2010
with 5 others
Phase 3
6 of 19
none open now
Registered
3rd of 19
by date

Among the 19 studies in Schizophrenia by Hoffmann-La Roche, this one is the 3rd largest by enrollment of the 16 interventional ones that give a count, is one of 6 that started in 2010, is one of 6 in phase 3, and was the 3rd registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

None of the 19 studies in Schizophrenia by Hoffmann-La Roche is open now. The open studies under Schizophrenia, anywhere →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies in Schizophrenia by Hoffmann-La Roche as a file.
02

Study summary

This multi-center, randomized, double blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 (bitopertin) in patients with persistent, predominant negative symptoms of schizophrenia. Patients, on stable treatment with antipsychotics, will be randomized to receive daily oral doses of RO4917838 or matching placebo for 52 weeks, followed by an optional treatment extension for up to 3 years.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients, aged 18 years and above
  • Diagnosis of schizophrenia of paranoid, disorganized, residual, undifferentiated or catatonic subtype
  • Predominant negative symptoms
  • With the exception of clozapine, patients are on any of the available marketed atypical or typical antipsychotics (treatment with a maximum of two antipsychotics)

Exclusion criteria

Exclusion Criteria:

  • Evidence that patient has , uncontrolled and unstable disorder (e.g. cardiovascular, renal, hepatic disorder)
  • (BMI) of \<17 or >40 kg/m2
  • Depressive symptoms, defined as a score of 9 or greater on the Calgary Depression Rating Scale for Schizophrenia (CDSS)
  • A severity score of 3 or greater on the Parkinsonism item of the ESRS-A (Clinical Global Impression, Parkinsonism)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
624 participants (actual)

Study arms

  • Experimental
    1

    Drug: bitopertin [RO4917838]

  • Experimental
    2

    Drug: bitopertin [RO4917838]

  • Placebo comparator
    3

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Efficacy (PANSS negative symptoms factor score)

    Time frame: Week 24

  2. Safety (incidence of adverse events)

    Time frame: Week 24

07

Study locations

113 sites
  • Carson, California 90746, United States
  • Oceanside, California 92056, United States
  • San Diego, California 92121, United States
  • San Diego, California 92123, United States
  • Hartford, Connecticut 06106, United States
  • Norwalk, Connecticut 06851, United States
  • North Miami, Florida 33161, United States
  • Atlanta, Georgia 30328, United States
  • Chicago, Illinois 60612, United States
  • Hoffman Estates, Illinois 60169, United States
  • Joliet, Illinois 60435, United States
  • Lake Charles, Louisiana 70601, United States
  • Shreveport, Louisiana 71104-2136, United States
  • St. Louis, Missouri 63128, United States
  • Omahac, Nebraska 68131, United States
  • Cedarhurst, New York 11516, United States
  • Jamaica, New York 11418, United States
  • Rochester, New York 14623, United States
  • Allentown, Pennsylvania 18104, United States
  • Norristown, Pennsylvania 19403, United States
  • Philadelphia, Pennsylvania 19139, United States
  • Salvador, BA 40301-500, Brazil
  • Goiania, GO 74093-040, Brazil
  • Belo Horizonte, MG 30150-270, Brazil
  • Curitiba, PR 80240-280, Brazil
  • Rio de Janeiro, RJ 22270-060, Brazil
  • Pelotas, RS 96030-002, Brazil
  • Porto Alegre, RS 90035-003, Brazil
  • Sao Paulo, SP 04044-000, Brazil
  • Sao Paulo, SP 05403-010, Brazil
  • Calgary, Alberta T2N 4Z6, Canada
  • Medicine Hat, Alberta T1B 4E7, Canada
  • Vancouver, British Columbia V5Z 3P1, Canada
  • Victoria, British Columbia V8R 4Z3, Canada
  • Halifax, Nova Scotia B3H 2E2, Canada
  • Burlington, Ontario L7R 4E2, Canada
  • Hamilton, Ontario L8N 3K7, Canada
  • Mississauga, Ontario L5M 4N4, Canada
  • Montreal, Quebec H1N 3M5, Canada
  • Montreal, Quebec H3A 1A1, Canada
  • Verdun, Quebec H4H 1R3, Canada
  • San Miguel, 8900000, Chile
  • Santiago, 7500710, Chile
  • Santiago, 7501126, Chile
  • Santiago, 8050000, Chile
  • Santiago, 8320000, Chile
  • Santiago, Chile
  • Valdivia, 5090000, Chile
  • Berlin, 10117, Germany
  • Bochum, 44805, Germany
  • Freiburg, 79104, Germany
  • Hamburg, 20246, Germany
  • Koeln, 50937, Germany
  • Muenchen, 81675, Germany
  • München, 80336, Germany
  • Nürnberg, 90402, Germany
  • Daugovpils, LV-5417, Latvia
  • Jelgava, LV-3008, Latvia
  • Liepaja, LV 3401, Latvia
  • Kaunas, 44279, Lithuania
  • Kaunas, 48259, Lithuania
  • Kaunas, 50009, Lithuania
  • Kaunas, 53136, Lithuania
  • Silute, 99142, Lithuania
  • Vilnius, 07156, Lithuania
  • Vilnius, 10204, Lithuania
  • Assen, 9400 RA, Netherlands
  • Groningen, 9700 AB, Netherlands
  • Groningen, 9713 GZ, Netherlands
  • Choroszcz, 16-070, Poland
  • Kielce, 25-103, Poland
  • Lublin, 20-015, Poland
  • Lublin, 20-045, Poland
  • Lublin, 20-080, Poland
  • Piekary Slaskie, 41-940, Poland
  • Skorzewo, 60-185, Poland
  • Tuszyn, 95-080, Poland
  • Warszawa, 02-957, Poland
  • Bojnice, 972 01, Slovakia
  • Bratislava, 820 07, Slovakia
  • Bratislava, 851 01, Slovakia
  • Rimavska Sobota, 97912, Slovakia
  • Svidnik, 089 01, Slovakia
  • Oviedo, Asturias 33011, Spain
  • Barcelona, 08036, Spain
  • Barcelona, 08304, Spain
  • Barcelona, 08830, Spain
  • Madrid, 28009, Spain
  • Madrid, 28040, Spain
  • Salamanca, 37007, Spain
  • Zamora, 49021, Spain
  • Hualian Town, 970, Taiwan
  • Kaohsiung, 80276, Taiwan
  • Taichung, 407, Taiwan
  • Tainan County, 717, Taiwan
  • Tainan, 704, Taiwan
  • Taipei, 00112, Taiwan
  • Taipei, 110, Taiwan
  • Ankara, 06100, Turkey
  • Diyarbakir, 21280, Turkey

Showing the first 100 of 113 sites across 14 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Georgiades A, Davis VG, Atkins AS, Khan A, Walker TW, Loebel A, Haig G, Hilt DC, Dunayevich E, Umbricht D, Sand M, Keefe RSE. Psychometric characteristics of the MATRICS Consensus Cognitive Battery in a large pooled cohort of stable schizophrenia patients. Schizophr Res. 2017 Dec;190:172-179. doi: 10.1016/j.schres.2017.03.040. Epub 2017 Apr 20. PubMed 28433500 ↗
  • Bugarski-Kirola D, Blaettler T, Arango C, Fleischhacker WW, Garibaldi G, Wang A, Dixon M, Bressan RA, Nasrallah H, Lawrie S, Napieralski J, Ochi-Lohmann T, Reid C, Marder SR. Bitopertin in Negative Symptoms of Schizophrenia-Results From the Phase III FlashLyte and DayLyte Studies. Biol Psychiatry. 2017 Jul 1;82(1):8-16. doi: 10.1016/j.biopsych.2016.11.014. Epub 2016 Dec 15. PubMed 28117049 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2010, a primary completion of Jul 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2010
First posted
Sep 1, 2010
Start
Dec 2010
Primary completionActual
Jul 2014
CompletionActual
Jul 2014
Results delay requested
Aug 20, 2013
Last update
Nov 2, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01192906
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Sep 1, 2010
Start date
Dec 2010
Primary completion
Jul 2014
Completion
Jul 2014
Last update
Nov 2, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bitopertin

Start the discussion